Genetic KCa3.1-Deficiency Produces Locomotor Hyperactivity and Alterations in Cerebral Monoamine Levels
Open Access
- 15 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e47744
Abstract
The calmodulin/calcium-activated K+ channel KCa3.1 is expressed in red and white blood cells, epithelia and endothelia, and possibly central and peripheral neurons. However, our knowledge about its contribution to neurological functions and behavior is incomplete. Here, we investigated whether genetic deficiency or pharmacological activation of KCa3.1 change behavior and cerebral monoamine levels in mice. In the open field test, KCa3.1-deficiency increased horizontal activity, as KCa3.1−/− mice travelled longer distances (≈145% of KCa3.1+/+) and at higher speed (≈1.5-fold of KCa3.1+/+). Working memory in the Y-maze was reduced by KCa3.1-deficiency. Motor coordination on the rotarod and neuromuscular functions were unchanged. In KCa3.1−/− mice, HPLC analysis revealed that turn-over rates of serotonin were reduced in frontal cortex, striatum and brain stem, while noradrenalin turn-over rates were increased in the frontal cortex. Dopamine turn-over rates were unaltered. Plasma catecholamine and corticosterone levels were unaltered. Intraperitoneal injections of 10 mg/kg of the KCa3.1/KCa2-activator SKA-31 reduced rearing and turning behavior in KCa3.1+/+ but not in KCa3.1−/− mice, while 30 mg/kg SKA-31 caused strong sedation in 50% of the animals of either genotypes. KCa3.1−/− mice were hyperactive (≈+60%) in their home cage and SKA-31-administration reduced nocturnal physical activity in KCa3.1+/+ but not in KCa3.1−/− mice. KCa3.1-deficiency causes locomotor hyperactivity and altered monoamine levels in selected brain regions, suggesting a so far unknown functional link of KCa3.1 channels to behavior and monoaminergic neurotransmission in mice. The tranquilizing effects of low-dose SKA-31 raise the possibility to use KCa3.1/KCa2 channels as novel pharmacological targets for the treatment of neuropsychiatric hyperactivity disorders.Keywords
This publication has 45 references indexed in Scilit:
- A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damageProceedings of the National Academy of Sciences, 2012
- Intermediate conductance calcium-activated potassium channels modulate summation of parallel fiber input in cerebellar Purkinje cellsProceedings of the National Academy of Sciences, 2012
- Control of hypothalamic–pituitary–adrenal stress axis activity by the intermediate conductance calcium‐activated potassium channel, SK4The Journal of Physiology, 2011
- The KCa3.1 Blocker TRAM-34 Reduces Infarction and Neurological Deficit in a Rat Model of Ischemia/Reperfusion StrokeJournal of Cerebral Blood Flow & Metabolism, 2011
- Calcium-Activated Potassium Channels BK and IK1 Are Functionally Expressed in Human Gliomas but Do Not Regulate Cell ProliferationPLOS ONE, 2010
- Endothelial dysfunction and blood pressure alterations in K+-channel transgenic micePflügers Archiv - European Journal of Physiology, 2010
- Vascular KCa-channels as therapeutic targets in hypertension and restenosis diseaseExpert Opinion on Therapeutic Targets, 2010
- Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a New Activator of KCa2 and KCa3.1 Potassium Channels, Potentiates the Endothelium-Derived Hyperpolarizing Factor Response and Lowers Blood PressureMolecular Pharmacology, 2009
- The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humansJournal of Clinical Investigation, 2008
- International Union of Pharmacology. LII. Nomenclature and Molecular Relationships of Calcium-Activated Potassium ChannelsPharmacological Reviews, 2005